Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 01, 2026
TickeronGET DAILY SIGNALS
Hinge Health (HNGE) Rises +9% Over the Past 30 Days on Growth Momentum

Hinge Health (HNGE) Rises +9% Over the Past 30 Days on Growth Momentum

Key Takeaways

  • HNGE shares have climbed roughly 9% over the trailing 30 days, holding near 52-week highs after a powerful 2026 run.
  • Second-quarter 2026 revenue rose 53% year over year to $213 million, while operating margin expanded to 29% from 19%.
  • The company signed a definitive agreement to acquire Cylinder Health for $105 million in cash, adding gastrointestinal care to its platform.
  • Full-year 2026 revenue guidance was raised to $856 million–$860 million, with non-GAAP operating income guided to $236 million–$244 million.
  • Analyst sentiment has turned constructive, with several firms issuing Buy ratings and raising price targets.

Where HNGE Stands in the Market Right Now

Hinge Health shares recently traded near $97.95, within striking distance of their 52-week highs and up roughly 9% over the prior 30 days. That short-term move extends a substantially larger year-to-date advance, reflecting strong demand for the stock after a record quarterly report and an upward revision to full-year guidance. The stock's elevated price-to-earnings multiple—in the range of roughly 70 times—signals that investors are pricing in continued rapid growth and margin expansion rather than current profitability alone. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Hinge Health’s (HNGE) Business and Competitive Position

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) health, covering the spectrum from acute injury and chronic pain to post-surgical rehabilitation. Its core platform, built around AI-powered motion-tracking technology and the Enso wearable for non-addictive pain relief, pairs software with a care team of licensed physical therapists, physicians, and health coaches. Founded in 2014 and headquartered in San Francisco, the company serves employers and health plans and has expanded into adjacent care categories, including migraine and gastrointestinal health. Its strategy centers on automating care delivery to improve member outcomes while lowering costs for clients, positioning Hinge Health as one of the most prominent names in virtual-first MSK care.

Key Drivers Behind Recent HNGE Momentum

The most significant recent catalyst was Hinge Health's second-quarter 2026 report, which showed revenue of $213 million—up 53% year over year and above the company's prior guidance range. Operating income more than doubled to $62 million, gross margin reached 87%, and free cash flow climbed to $100 million from $33 million a year earlier. Last-twelve-month calculated billings rose 52% to $862 million, a leading indicator management highlights for future revenue growth. From what I see, these results underscore the durability of the company’s growth trajectory.

Alongside the results, Hinge Health raised its 2026 outlook, citing durable improvements in member engagement, or "yield." The company now expects full-year revenue of $856 million to $860 million and non-GAAP operating income of $236 million to $244 million. Management also announced a $300 million share-repurchase authorization after repurchasing roughly 480,000 shares for $26 million during the quarter.

The company's expansion strategy has drawn particular attention. Hinge Health signed a definitive agreement to acquire Cylinder Health, a virtual-first gastrointestinal care provider with nearly 100 clients covering about 2 million lives, for $105 million in cash. The deal is expected to contribute roughly $7 million to $8 million of revenue in 2026, with broader scaling anticipated in 2027 and beyond. Separately, the company's newer Migraine Care Program has enrolled more than 450 clients covering over 5 million lives. Analyst activity has reflected this momentum, with Bank of America initiating coverage with a Buy rating and a $110 target, while Stifel and Needham raised their price targets to $115.

2026 Outlook and Areas Investors Should Monitor

Looking ahead, investors will likely focus on the third-quarter 2026 report, where management has guided to revenue of $223 million to $225 million—roughly 45% growth at the midpoint. Sustained yield improvements, growth in eligible lives, and average selling price per member remain the key drivers of the company's billings trajectory. I’m watching this closely as execution on these fronts will determine whether the current valuation holds.

The Cylinder Health integration is another area to monitor, with completion targeted by summer 2027 and a broader gastrointestinal rollout planned for 2027. Because the business is expected to operate at a loss initially, execution on integration and its path toward Hinge Health's profitability profile will be closely watched. Broader themes—including employer and health-plan budget cycles, competition in virtual care, and healthcare spending conditions—also matter for the company's land-and-expand model. At current valuation levels, continued delivery on growth and margin targets will be central to how the market assesses the stock's premium.

Exploring Tickeron’s Trending AI Robots

In my analysis of names like HNGE, I often turn to Tickeron’s Trending AI Robots page for an additional perspective. It surfaces a selection of high-performing AI-driven trading bots that cover various strategies and timeframes, helping me evaluate momentum signals alongside traditional research. This resource has become a useful part of my routine when assessing growth stocks in the healthcare space.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HNGE

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


HNGE in downward trend: price dove below 50-day moving average on November 20, 2026

HNGE moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend. In 7 of 7 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for HNGE moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In 2 of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at 25%.

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HNGE as a result. In 23 of 28 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for HNGE turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 12 similar instances when the indicator turned negative. In 9 of the 12 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HNGE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where HNGE advanced for three days, in 82 of 96 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

HNGE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 75 of 84 cases where HNGE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. HNGE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HNGE's P/B Ratio (27.129) is slightly higher than the industry average of (4.523). P/E Ratio (14.015) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (10.504) is also within normal values, averaging (6.105).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HNGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -13%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 2%. DRIO experienced the highest price growth at 5%, while LFMD experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 27%. For the same stocks of the Industry, the average monthly volume growth was 34% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -5 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Industry
N/A
Address
455 Market Street
Phone
+1 415 726-2206
Employees
1437
Web
https://www.hingehealth.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.